Your browser doesn't support javascript.
loading
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.
Harmanen, Minna; Klaavuniemi, Tuula; Sorigue, Marc; Khan, Madiha; Prusila, Roosa; Kari, Esa; Alanne, Erika; Rajamäki, Aino; Sunela, Kaisa; Jukkola, Arja; Jantunen, Esa; Sancho, Juan-Manuel; Ketola, Sanna; Kuitunen, Hanne; Selander, Tuomas; Rönkä, Aino; Kuittinen, Outi.
Afiliación
  • Harmanen M; Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
  • Klaavuniemi T; Department of Oncology, Mikkeli Central Hospital, Southern Savonia Municipality District, Mikkeli, Finland.
  • Sorigue M; Department of Hematology, ICO-Badalona, Hospital Germans Trias i Pujol, IJC, LUMN, Badalona, Spain.
  • Khan M; Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
  • Prusila R; Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
  • Kari E; Cancer Center and Medical Research Center, Oulu University Hospital, Oulu, Finland.
  • Alanne E; Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Rajamäki A; Department of Oncology and Radiotherapy, Turku University Hospital, Western Finland, Cancer Center, Turku, Finland.
  • Sunela K; Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital Cancer Center, Kuopio, Finland.
  • Jukkola A; Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Jantunen E; Department of Oncology, Hospital Nova of Central Finland, Jyväskylä, Finland.
  • Sancho JM; Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Ketola S; Finnish Medicines Agency, Tampere, Finland.
  • Kuitunen H; Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Selander T; Institute of Clinical Medicine, University of Eastern Finland and Department of Medicine, North Carelia Central Hospital, Joensuu, Finland.
  • Rönkä A; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Kuittinen O; Department of Hematology, ICO-Badalona, Hospital Germans Trias i Pujol, IJC, LUMN, Badalona, Spain.
Hemasphere ; 7(10): e954, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37693119
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Hemasphere Año: 2023 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Hemasphere Año: 2023 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos